Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kedem Pharmaceuticals has entered a contract with Corealis Pharma, a GMP pharmaceutical FDA compliant formulation development company, for the production of the phase I clinical supplies of therapeutic drug, KDM-1102.
Subscribe to our email newsletter
The KDM-1102 drug is a new sublingual formulation of propanolol whose formulation development is now completed and can be produced in large volume.
The sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection thereby helping in rapid absorption through the mucosal membrane.
Kedem Pharmaceuticals president and CEO Hassan Salari said the company is glad with the advancement in the development program on KDM-1102, their Second lead therapeutic drug for cardiovascular and anxiety attacks.
Corealis Pharma is a contractual formulation development and clinical supply manufacturing company of pharmaceutical oral solid dosage forms for United-States, European, and Canadian trials.